CD8A and non-small cell lung carcinoma: In addition to the above, several clinical trials using liposomes as carrier system for vaccine have reported safety, capability of inducing prolonged antigen-specific CD4+ and CD8+ T cell responses, as well as prolonged survival in various cancers, including non-small-cell lung carcinoma (NSCLC) (166), melanoma (167, 168), follicular lymphoma (169) ovarian (170), breast and prostate cancers (171).